Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | STS | P08842 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557597 | 0.95 | DRD2 (0.61) | MEN1KMT2ADRD2KDM4ESTS | |
| SCHEMBL29691893 | 0.88 | RORC (0.48) | MEN1KMT2ADRD2CA12CA1 | |
| SCHEMBL15804316 | 0.88 | MEN1 (0.49) | MEN1KMT2ADRD2KDM4ESTS | |
| SCHEMBL1239091 | 0.88 | RORC (0.48) | MEN1KMT2ADRD2CCR1 | |
| SCHEMBL655150 | 0.87 | DRD2 (0.56) | MEN1KMT2ADRD2KDM4ESTS | |
| SCHEMBL15595091 | 0.87 | TSHR (0.53) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL16874679 | 0.86 | ALDH1A1 (0.51) | MEN1KMT2ASTSALDH1A1SMN1; SMN2 | |
| SCHEMBL15595071 | 0.86 | MEN1 (0.48) | MEN1KMT2ADRD2STSALDH1A1 | |
| SCHEMBL29691772 | 0.85 | RORC (0.48) | MEN1KMT2ADRD2MAPTCA12 | |
| SCHEMBL12489308 | 0.84 | GPR119 (0.50) | MEN1KMT2ADRD2ALDH1A1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1688418-A2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1448566-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030045516-A1 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-6509346-B2 | Antiinflammatory agents | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | MEN1 4193/4885KMT2A 4608/4885DRD2 3688/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | MEN1 2347/4885KMT2A 3725/4885DRD2 4501/4885 |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | MEN1 4609/4885KMT2A 4640/4885DRD2 3542/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-20250034125-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-20030045516-A1 | Chemokine receptor antagonists and methods of use therefor | CCL11, ACKR3, CXCR4 | MEN1 4202/4885KMT2A 4625/4885DRD2 3720/4885 |
| US-20210139471-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | MEN1 191/4885KMT2A 587/4885DRD2 2063/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | MEN1 4673/4885KMT2A 1082/4885DRD2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.